Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTR2C polymorphisms and metabolic adverse effects of mirtazapine versus paroxetine
NL-OMON30967Active, not recruiting
- Sponsor
- Orbis Medisch Centrum
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of mirtazapine and paroxetine in major depressive disorder (MDD) (2 arms), sponsored by Orbis Medisch Centrum. Primary endpoints: BMI increase and Waist circumference increase. Started Apr 2008; status: active, not recruiting.
02
Drugs
mirtazapineparoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON30967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30967.